Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Oct 17

PMID 30321986

Citations 24

Authors

Julia Wanek

Martin Gaisberger

Marlena Beyreis

Christian Mayr

Katharina Helm

Florian Primavesi

Tarkan Jager

Pietro Di Fazio

Martin Jakab

Andrej Wagner

Daniel Neureiter

Tobias Kiesslich

Affiliations

Soon will be listed here.

Abstract

Histone deacetylases (HDACs) play a key role in epigenetic mechanisms in health and disease and their dysfunction is implied in several cancer entities. Analysis of expression patterns in pancreatic neuroendocrine tumors (pNETs) indicated HDAC5 to be a potential target for future therapies. As a first step towards a possible treatment, the aim of this study was to evaluate the in vitro cellular and molecular effects of HDAC5 inhibition in pNET cells. Two pNET cell lines, BON-1 and QGP-1, were incubated with different concentrations of the selective class IIA HDAC inhibitor, LMK-235. Effects on cell viability were determined using the resazurin-assay, the caspase-assay, and Annexin-V staining. Western Blot and immunofluorescence microscopy were performed to assess the effects on HDAC5 functionality. LMK-235 lowered overall cell viability by inducing apoptosis in a dose- and time-dependent manner. Furthermore, acetylation of histone-H3 increased with higher LMK-235 concentrations, indicating functional inhibition of HDAC4/5. Immunocytochemical analysis showed that proliferative activity (phosphohistone H3 and Ki-67) decreased at highest concentrations of LMK-235 while chromogranin and somatostatin receptor 2 (SSTR2) expression increased in a dose-dependent manner. HDAC5 expression was found to be largely unaffected by LMK-235. These findings indicate LMK-235 to be a potential therapeutic approach for the development of an effective and selective pNET treatment.

Citing Articles

Development of Glutathione Hydrogel Carriers Containing Zinc Oxide Microparticles for Skin Regeneration Processes.

Trager D, Mlyniec K, Harazna K, Slota D, Niziolek K, Jampilek J Int J Mol Sci. 2025; 26(4).

PMID: 40003863 PMC: 11855678. DOI: 10.3390/ijms26041395.

Design and radiosynthesis of class-IIa HDAC inhibitor with high molar activity via repositioning the F-radiolabel.

Xu S, Huang C, Eyermann C, Georgakis G, Turkman N Sci Rep. 2024; 14(1):15100.

PMID: 38956204 PMC: 11219833. DOI: 10.1038/s41598-024-65668-z.

Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.

Saleh Z, Moccia M, Ladd Z, Joneja U, Li Y, Spitz F Int J Mol Sci. 2024; 25(2).

PMID: 38279330 PMC: 10816436. DOI: 10.3390/ijms25021331.

Epigenetic regulation of SST expression in small intestinal neuroendocrine tumors.

Klomp M, Refardt J, Van Koetsveld P, Campana C, Dalm S, Dogan F Front Endocrinol (Lausanne). 2023; 14:1184436.

PMID: 37223009 PMC: 10200989. DOI: 10.3389/fendo.2023.1184436.

Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.

Ullrich M, Richter S, Liers J, Drukewitz S, Friedemann M, Kotzerke J Theranostics. 2023; 13(1):278-294.

PMID: 36593963 PMC: 9800739. DOI: 10.7150/thno.77918.

References

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

Frye R, Myers M, Axelrod K, Ness E, Piekarz R, Bates S . Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. Clin J Oncol Nurs. 2012; 16(2):195-204. PMC: 7243910. DOI: 10.1188/12.CJON.195-204. View

He P, Liang J, Shao T, Guo Y, Hou Y, Li Y . HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression. Int J Clin Exp Med. 2015; 8(4):6510-6. PMC: 4483821. View

Fan J, Lou B, Chen W, Zhang J, Lin S, Lv F . Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. Tumour Biol. 2014; 35(11):11523-32. DOI: 10.1007/s13277-014-2358-2. View

Detre S, Saclani Jotti G, Dowsett M . A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995; 48(9):876-8. PMC: 502883. DOI: 10.1136/jcp.48.9.876. View

Mayr C, Helm K, Jakab M, Ritter M, Shrestha R, Makaju R . The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer. Hum Pathol. 2017; 72:117-126. DOI: 10.1016/j.humpath.2017.11.003. View

Marek L, Hamacher A, Hansen F, Kuna K, Gohlke H, Kassack M . Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2012; 56(2):427-36. DOI: 10.1021/jm301254q. View

Ye M, Fang Z, Gu H, Song R, Ye J, Li H . Histone deacetylase 5 promotes the migration and invasion of hepatocellular carcinoma via increasing the transcription of hypoxia-inducible factor-1α under hypoxia condition. Tumour Biol. 2017; 39(6):1010428317705034. DOI: 10.1177/1010428317705034. View

West A, Johnstone R . New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124(1):30-9. PMC: 3871231. DOI: 10.1172/JCI69738. View

10.

Peixoto P, Castronovo V, Matheus N, Polese C, Peulen O, Gonzalez A . HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells. Cell Death Differ. 2012; 19(7):1239-52. PMC: 3374087. DOI: 10.1038/cdd.2012.3. View

11.

Cecconi D, Donadelli M, Rinalducci S, Zolla L, Scupoli M, Scarpa A . Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. Proteomics. 2007; 7(10):1644-53. DOI: 10.1002/pmic.200600811. View

12.

Liu C, Lv D, Li M, Zhang X, Sun G, Bai Y . Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer. Int J Oncol. 2017; 50(6):2079-2090. DOI: 10.3892/ijo.2017.3967. View

13.

Huang Y, Tan M, Gosink M, Wang K, Sun Y . Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res. 2002; 62(10):2913-22. View

14.

Schimmack S, Svejda B, Lawrence B, Kidd M, Modlin I . The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg. 2011; 396(3):273-98. DOI: 10.1007/s00423-011-0739-1. View

15.

Reid M, Balci S, Saka B, Adsay N . Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr Pathol. 2014; 25(1):65-79. DOI: 10.1007/s12022-013-9295-2. View

16.

Berardi R, Rinaldi S, Torniai M, Morgese F, Partelli S, Caramanti M . Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review. Crit Rev Oncol Hematol. 2015; 98:264-74. DOI: 10.1016/j.critrevonc.2015.11.003. View

17.

Narayanan S, Kunz P . Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2015; 30(1):163-77. DOI: 10.1016/j.hoc.2015.09.008. View

18.

Zhao M, Li L, Zhou J, Cui X, Tian Q, Jin Y . MiR-2861 Behaves as a Biomarker of Lung Cancer Stem Cells and Regulates the HDAC5-ERK System Genes. Cell Reprogram. 2018; 20(2):99-106. DOI: 10.1089/cell.2017.0045. View

19.

Werner R, Ilhan H, Lehner S, Papp L, Zsoter N, Schatka I . Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. Mol Imaging Biol. 2018; 21(3):582-590. DOI: 10.1007/s11307-018-1252-5. View

20.

McDermott J, Jimeno A . Belinostat for the treatment of peripheral T-cell lymphomas. Drugs Today (Barc). 2014; 50(5):337-45. DOI: 10.1358/dot.2014.50.5.2138703. View